the data suggest that bis-choline tetrathiomolybdate can rapidly lower and control toxic free copper levels and improve clinical symptoms in wilson's disease patients. the data also suggest that it is generally well-tolerated with the potential for a reduced risk of neurological worsening after initiation of therapy compared to existing therapies.